« Return to News | Drug Sponsors

Forma and Janssen to collaborate on cancer drug

Wednesday, January 11, 2012 11:19 AM

Forma Therapeutics has formed an exclusive alliance with Janssen Biotech (a subsidiary of Johnson & Johnson), in which the pair will collaborate on discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

"This collaboration will enable a broad chemical biology approach to understanding the unique biology underlying cancer metabolism,” said Kenneth Bair, Ph.D., senior vice president and head of R&D at Forma.

 Forma will discover and develop drugs against a panel of tumor metabolism targets, with the possibility of $700 million in milestone payments from Janssen. Both companies are allowed to expand the collaboration to include additional targets, even in areas beyond tumor metabolism.

Forma will also be eligible for royalties on revenues from commercialized products as a result of the collaboration, and it will have the opportunity to co-develop and maintain North American commercial rights to one program of Janssen’s choosing.

“This collaboration with Janssen Biotech further strengthens our drug discovery capabilities and also allows us to look to the future with an opportunity to maintain North American rights, which is a key element of our strategy to create long-term shareholder value within Forma," said Steven Tregay, Ph.D., CEO of Forma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.